The Short-Term Verdict on Long-Acting Antiretrovirals

We talk with Chloe Orkin, M.D., about one aspect of our future that in some very concrete ways has already arrived, and yet is currently out of reach for millions: long-acting medical interventions for HIV, the first of which were approved in the U.S. and Europe for treatment over a year ago and approved in the U.S. for prevention late last year. The beginning of the long-acting era has revealed anew some longstanding questions regarding who these drugs primarily benefit, who is able to receive them, and how our entire medical system is set up to serve -- or not serve -- the people who can most benefit from it.   Dr. Orkin is a professor of HIV medicine at Queen Mary University of London and the president of the Medical Women's Federation. She is one of world's leading minds in HIV research in medicine -- as well as one of the leading voices in conversations about health equity, access, and anti-discrimination.   Read the full transcript (clicking the link also helps support the podcast!): https://www.thebodypro.com/article/future-hiv-care-podcast-3-long-acting-antiretrovirals     Our podcast team: Episode host and executive producer Myles Helfand; audio producers/engineers Alex Portaluppi and Lucy Mueller; project manager Alina Mogollon-Volk; and podcast editors Maria Elena Perez and Juan Michael Porter II.